Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions.

Our approach is based upon a unique mechanism of action of decoy agonist interfering with DNA Damage Response. We focus on bringing first-in-class and disruptive compounds from translational research to proof-of-concept in man in cancer indications with high unmet needs.

STRONG EXPERTISE &
CLEAR STRATEGY

Leveraging our knowledge of cancer cell biology and tumor DNA Damage Response mechanisms with translational & clinical expertise
Driving programs to best inflection points and generate value through licensing agreements
Supported by world-class scientific & medical advisors and clinicians, global KOL and academia network

LEARN ABOUT US

UNIQUE SCIENCE IN
DNA DAMAGE RESPONSE

platON™, platform of oligonucleotides, to generate innovative compounds targeting tumor DNA-binding functions through a decoy mechanism with an agonist effect
Distinctive mechanisms of action to address high unmet needs in multiple cancer indications with rapid path to market
Capacity to address new & multiple pathways and to target both DDR and immune response

DISCOVER OUR SCIENCE

AsiDNA™, A DECOY AGONIST
INHIBITING THE DDR

First-in-class product in DDR, AsiDNA™, currently in clinical trials, with potential in multiple indications and combo therapies
The only decoy agonist in development, acting upstream of multiple DDR pathways to disrupt and exhaust the tumor DNA Damage Response without inducing resistance
Strong synergy with DNA-damaging agents and targeted therapies, ability to prevent and reverse tumor resistance to treatments

EXPLORE OUR PIPELINE